Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site

Mod Rheumatol Case Rep. 2021 Jan;5(1):62-68. doi: 10.1080/24725625.2020.1789302. Epub 2020 Jul 9.

Abstract

A 71-year-old woman with dermatomyositis (DM) received glucocorticoid steroid (GCS) and tacrolimus treatment. Relapse of skin symptoms was observed after tapering the GCS dose, and the patient tested positive for anti-transcriptional intermediary factor-1 gamma (TIF1-γ) antibody. Examinations for malignancy were repeatedly performed. However, no obvious findings indicative of a tumour were observed. Two years after, a retroperitoneal tumour was detected and pathologically diagnosed as poorly differentiated adenocarcinoma. The patient developed intestinal and biliary obstruction and eventually died of sepsis. Herein, we report the presence of anti-TIF1-γ antibodies in a DM patient with cancer of unknown primary site.

Keywords: Idiopathic inflammatory myopathy; anti-TIF1-γ antibody; cancer of unknown primary site; dermatomyositis; retroperitoneal tumour.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / complications*
  • Adenocarcinoma / pathology
  • Aged
  • Autoantibodies / blood*
  • Autoantibodies / immunology
  • Dermatomyositis / blood
  • Dermatomyositis / complications*
  • Dermatomyositis / diagnosis
  • Fatal Outcome
  • Female
  • Humans
  • Neoplasms, Unknown Primary
  • Positron Emission Tomography Computed Tomography
  • Retroperitoneal Neoplasms / complications*
  • Retroperitoneal Neoplasms / diagnosis
  • Transcription Factors / immunology*

Substances

  • Autoantibodies
  • Transcription Factors